ORIGINAL RESEARCH article

Front. Immunol.

Sec. Cytokines and Soluble Mediators in Immunity

Volume 16 - 2025 | doi: 10.3389/fimmu.2025.1526439

This article is part of the Research TopicCommunity Series in Autoantibodies: Volume IIView all 11 articles

Concomitant Autoimmunity and Late Cancers in Adult-Onset Immunodeficiency Due to Neutralizing Anti-IFN-γ Autoantibodies

Provisionally accepted
Wan-Ting  TsaiWan-Ting Tsai1Chih-Yun  ChengChih-Yun Cheng2Hsin-Yun  SunHsin-Yun Sun3Bei-Chia  GuoBei-Chia Guo4Ying-Chieh  ChiangYing-Chieh Chiang4Chiao-Feng  ChengChiao-Feng Cheng3Yi-Hua  PanYi-Hua Pan4Un-In  WuUn-In Wu3Jann-Tay  WangJann-Tay Wang3Wang-Huei  ShengWang-Huei Sheng3Aristine  ChengAristine Cheng3*Yee-Chun  ChenYee-Chun Chen3Shan-Chwen  ChangShan-Chwen Chang3
  • 1Taipei City Hospital, Taipei, Taiwan
  • 2National Taiwan University Hospital Hsin-Chu Branch, Hsinchu, Hsinchu County, Taiwan
  • 3National Taiwan University Hospital, Taipei, Taiwan
  • 4National Taiwan University, Taipei, Taiwan

The final, formatted version of the article will be published soon.

Opportunistic intramacrophagic infections are well-characterized in adult-onset immunodeficiency associated with neutralizing anti-IFN-γ autoantibodies (nAIGA). Concomitant autoimmune and neoplastic diseases are rarely described. This study included 50 patients diagnosed with adult-onset immunodeficiency due to nAIGA between 2014-2024. Thirty-three were retrospectively included before January 2022, and 17 out of 295 screened patients were enrolled prospectively since January 2022. Ten patients were excluded due to missing records. All patients had regular follow-ups; anti-IFN-γ titers, autoimmune markers and cancer survey were conducted according to the primary physician's evaluation.The median age at diagnosis of adult-onset immunodeficiency was 57 years, and 53% were men. Malignancy occurred in 25%; genitourinary cancer predominated (n=4). Most (93%) patients had at least one positive autoimmune marker. Fifty-eight percent of patients were diagnosed with concomitant autoimmune diseases, and women (65%) predominated. Anti-nuclear antibody was positive in 61%, lupus anticoagulant in 50%, whilst autoimmune thyroiditis markers in 43%.Twenty-two percent of patients required long-term immunomodulation including biologic agents such as rituximab and daratumumab. Three patients (8%) died after a median interval of 9.4 years due to sepsis (n=2) and aggressive urothelial cancer (n=1). Most patients had decreasing nAIGA titers over time; two outliers with persistently high neutralizing antibodies developed late-onset malignancies.Adult-onset immunodeficiency due to nAIGA is a syndrome associated with concomitant autoimmunity. Chronic infection and autoimmune-mediated inflammation may foster neoplastic changes, but the underlying mechanism is still undetermined. Autoimmune disease and cancer surveillance for patients with nAIGA is advised.

Keywords: anti-interferon-γ autoantibody, Autoimmunity, secondary immunodeficiency, urothelial carcinoma, Papillary thyroid carcinoma, autoimmune thyroiditis ANA, anti-nuclear antibody, Anti-SSa, anti-Sjogren's Syndrome A, Anti-SSb, anti-Sjogren's 50 Syndrome B

Received: 11 Nov 2024; Accepted: 24 Mar 2025.

Copyright: © 2025 Tsai, Cheng, Sun, Guo, Chiang, Cheng, Pan, Wu, Wang, Sheng, Cheng, Chen and Chang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

* Correspondence: Aristine Cheng, National Taiwan University Hospital, Taipei, 100, Taiwan

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Research integrity at Frontiers

94% of researchers rate our articles as excellent or good

Learn more about the work of our research integrity team to safeguard the quality of each article we publish.


Find out more